3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
33
Cetuximab
16
Cisplatin
10
Radiotherapy
8
Paclitaxel
8
Docetaxel
8
atezolizumab
7
Fluorouracil
7
cemiplimab
6
Drug Therapy
6
budigalimab
5
Gemcitabine
5
Cyclophosphamide
5
Blood Specimen Collection
5
trametinib
4
Pemetrexed
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Bleomycin
4
Bevacizumab
4
palbociclib
3
fludarabine
3
durvalumab
3
dabrafenib
3
avelumab
3
Trastuzumab
3
Oxaliplatin
3
Interleukin-2
3
Indocyanine Green
3
Immunotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
nanocis
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled